Premium
Toward a postbiotic era of microbiome science: Opportunities to advance immunotherapies for hepatocellular carcinoma
Author(s) -
Nakatsu Geicho
Publication year - 2022
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1111/jgh.15715
Subject(s) - hepatocellular carcinoma , medicine , microbiome , immune checkpoint , blockade , immunity , cancer , liver cancer , immunotherapy , immune system , immunology , gut microbiome , fecal bacteriotherapy , cancer research , gut flora , bioinformatics , biology , receptor , clostridium difficile , microbiology and biotechnology , antibiotics
The microbiome has revolutionized the field of cancer immunology and checkpoint therapeutics for gastrointestinal malignancies. Combating hepatocellular carcinoma (HCC) by immune checkpoint blockade (ICB) is a unique challenge due in part to chronic complications that arise from local and systemic metabolic dysfunctions. Gut microbial metabolites modulate key immunological processes that influence liver cancer susceptibility and resistance to ICB. This review discusses recent progresses in linking microbiota functions to HCC tumor immunity and highlights their therapeutic potential.